Petrichor Bolsters Team with Industry Veteran
Growth-focused healthcare and life sciences private investment firm Petrichor has named Paul J. Sekhri as Operating Partner, adding an executive with more than 35 years of experience across biotech and pharmaceutical sectors, according to Private Equity Wire. Sekhri currently serves as Chairman, President, and CEO of vTv Therapeutics, and he has held senior leadership positions at eGenesis, Lycera Corporation, and Cerimon Pharmaceuticals.
Sekhri’s Extensive Background
Sekhri has taken on strategic roles at Sanofi, Teva, TPG Biotech, ARIAD Pharmaceuticals, and Novartis, enhancing his expertise in the field. He serves on more than 40 public and private company boards, including specific positions at Veeva Systems, Kayothera, and Deep Genomics. Additionally, Sekhri holds chairmanships at Resolution Therapeutics and Violet Therapeutics, further demonstrating his influence in the industry.
Petrichor’s Investment Profile
Petrichor Founder and Managing Partner Tadd Wessel described Sekhri as “a proven leader across biotech and big pharma whose expertise will strengthen our ability to support healthcare innovators at all stages of development.” The firm has completed over 125 healthcare investments and deployed more than $6 billion in capital, while maintaining extensive board representation across its portfolio. In the context of the life sciences sector, which is known for rapid innovation, such appointments can align with broader industry trends.
Implications for Petrichor’s Strategy
Petrichor’s appointment of Sekhri aligns with its focus on healthcare and life sciences, as his experience bolsters the firm’s capabilities in supporting innovators. According to Private Equity Wire, this move comes as Petrichor continues to build its team amid ongoing investments, reflecting the firm’s established track record in the sector.
